Research programme: factor Xa inhibitors - Eli Lilly
Latest Information Update: 31 Jul 2008
At a glance
- Originator Eli Lilly
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Mar 2005 Preclinical trials in Thrombosis in USA (PO)
- 20 Sep 2000 Preclinical development for Thrombosis in USA (unspecified route)